Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide

Haematologica

Volumn 102, Issue 5, 2017, Pages 932-940

  Kanakry, Christopher G ^a   Bakoyannis, Giorgos ^b   Perkins, Susan M ^b   McCurdy, Shannon R ^a   Vulic, Ante ^a   Warren, Edus H ^c   Daguindau, Etienne ^b   Olmsted, Taylor ^b   Mumaw, Christen ^b   Towlerton, Andrea M H ^c   Cooke, Kenneth R ^a   O’Donnell, Paul V ^c   Symons, Heather J ^a   Paczesny, Sophie ^b   Luznik, Leo ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BUSULFAN; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; MYCOPHENOLATE MOFETIL; PANCREATITIS ASSOCIATED PROTEIN; PLASMA PROTEIN; REGENERATING ISLET DERIVED ALPHA 3; TACROLIMUS; TIPRELESTAT; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; ALKYLATING AGENT; HLA ANTIGEN; IL1RL1 PROTEIN, HUMAN; REG3A PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER GRADING; CANCER RECURRENCE; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; PROSPECTIVE STUDY; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; ALLOTRANSPLANTATION; BLOOD; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HISTOCOMPATIBILITY TEST; MIDDLE AGED; MORTALITY; PROCEDURES; SURVIVAL RATE; TIME FACTOR; TRANSPLANTATION CONDITIONING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOMARKERS; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PANCREATITIS-ASSOCIATED PROTEINS; PROSPECTIVE STUDIES; PROTEOMICS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 85018965043     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.152322     Document Type: Article

References (46)

1. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(2):132.
2. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650.
3. McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024-3031.
4. Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single- agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115(16):3224-3230.
5. Kanakry CG, Tsai HL, Bolanos-Meade J, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014; 124(25):3817-3827.
6. Kanakry CG, O'Donnell PV, Furlong T, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014; 32(31):3497-3505.
7. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant. 1996;17(2):185-190.
8. Foley R, Couban S, Walker I, et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Bone Marrow Transplant. 1998;21(8):769-773.
9. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant. 1998;21(1):29-32.
10. Kitko CL, Paczesny S, Yanik G, et al. Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. Biol Blood Marrow Transplant. 2008;14(7):759-765.
11. Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood. 2008;112(4):1539-1542.
12. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113(2):273-278.
13. Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010; 2(13):13ra12.
14. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-6708.
15. Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012; 119(12):2960-2963.
16. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012; 119(16):3854-3860.
17. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529-539.
18. Kitko CL, Levine JE, Storer BE, et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood. 2014;123(5):786-793.
19. Holtan SG, Verneris MR, Schultz KR, et al. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant. 2015; 21(6):1029-1036.
20. Ponce DM, Hilden P, Mumaw C, et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2015;125(1):199-205.
21. McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood. 2015;126(1):113-120.
22. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75(4): 1011-1016.
23. Abu Zaid M, Wu J, Wu C, et al. Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. Blood. 2016;129(2):162-170.
24. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135(5):3172-3177.
25. Coghill JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood. 2011;117(12):3268-3276.
26. Holler E, Kolb HJ, Hintermeier-Knabe R, et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc. 1993;25(1 Pt 2):1234-1236.
27. Matta BM, Lott JM, Mathews LR, et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol. 2014;193(8):4010-4020.
28. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513(7519):564-568.
29. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011; 89(2):207-215.
30. Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006;313(5790):1126-1130.
31. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14(3):282-289.
32. Ogawa H, Fukushima K, Naito H, et al. Increased expression of HIP/PAP and regenerating gene III in human inflammatory bowel disease and a murine bacterial reconstitution model. Inflamm Bowel Dis. 2003; 9(3):162-170.
33. Alkemade JA, Molhuizen HO, Ponec M, et al. SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J Cell Sci. 1994;107(Pt 8):2335-2342.
34. Symons HJ, Chen A, Gamper C, et al. Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/Cy) has limited toxicity and promising efficacy in largest reported experience with high risk hematologic malignancies. Biol Blood Marrow Transplant. 2015;21(2):S29-S29.
35. Fiema B, Harris AC, Gomez A, et al. High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease. J Vis Exp. 2012;68. pii 4247.
36. Bakoyannis G, Touloumi G. Practical methods for competing risks data: a review. Stat Methods Med Res. 2012;21(3):257-272.
37. Saha P, Heagerty PJ. Time-dependent predictive accuracy in the presence of competing risks. Biometrics. 2010;66(4):999-1011.
38. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Stat Med. 1999;94(446):496-509.
39. Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat. 1978;5:141-150.
40. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
41. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-458.
42. Kanakry CG, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157.
43. Ganguly S, Ross DB, Panoskaltsis-Mortari A, et al. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014; 124(13):2131-2141.
44. Kasamon YL, Bolanos-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015; 33(28):3152-3161.
45. McClune BL, Ahn KW, Wang HL, et al. Allotransplantation for patients age >/=40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014;20(7):960-968.
46. US National Library of Medicine. ClinicalTrials.gov [online]; 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT01879072. Last Accessed: 21st December 2016.